Literature DB >> 10614649

Tumor necrosis factor alpha regulates alpha(v)beta5 integrin expression by osteoclast precursors in vitro and in vivo.

M Inoue1, F P Ross, J M Erdmann, Y Abu-Amer, S Wei, S L Teitelbaum.   

Abstract

Early osteoclast precursors, in the form of murine bone marrow macrophages (BMMs), while expressing no detectable alpha(v)beta3 integrin, contain abundant alpha(v)beta5 and attach to matrix in an alpha(v) integrin-dependent manner. Furthermore, alpha(v)beta5 expression by osteoclast precursors progressively falls as they assume the resorptive phenotype. We find the osteoclastogenic agent, tumor necrosis factor-alpha, (TNF) down-regulates alpha(v)beta5 expression by BMMS via attenuation of beta5 messenger RNA (mRNA) t1/2. Using BMMs from TNF receptor knockout mice we establish the p55 receptor transmits the beta5 suppressive effect. The functional implications of TNF-mediated alpha(v)beta5 down-regulation are underscored by the capacity of an alpha(v) inhibitory peptide mimetic to prevent spreading by BMMs expressing abundant alpha(v)beta5 while failing to impact those in which the integrin has been diminished by TNF. Finally, beta5 mRNA in BMMs of wild-type mice administered lipopolysaccharide (LPS) progressively falls with time of in vivo treatment. Alternatively, beta5 mRNA does not decline in BMMs of LPS-treated mice lacking both TNF receptors, documenting down-regulation of the beta5 integrin subunit, in vivo, is mediated by TNF. Thus, matrix attachment of osteoclast precursors and mature osteoclasts are governed by distinct alpha(v) integrins which are differentially regulated by specific cytokines.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10614649     DOI: 10.1210/endo.141.1.7285

Source DB:  PubMed          Journal:  Endocrinology        ISSN: 0013-7227            Impact factor:   4.736


  9 in total

1.  Cloning and characterization of osteoclast precursors from the RAW264.7 cell line.

Authors:  Bethany L V Cuetara; Tania N Crotti; Anthony J O'Donoghue; Kevin P McHugh
Journal:  In Vitro Cell Dev Biol Anim       Date:  2006 Jul-Aug       Impact factor: 2.416

2.  Paxillin contracts the osteoclast cytoskeleton.

Authors:  Wei Zou; Carl J Deselm; Thomas J Broekelmann; Robert P Mecham; Scott Vande Pol; Kyunghee Choi; Steven L Teitelbaum
Journal:  J Bone Miner Res       Date:  2012-12       Impact factor: 6.741

Review 3.  Integrin alpha V beta 3 as a target for treatment of rheumatoid arthritis and related rheumatic diseases.

Authors:  R L Wilder
Journal:  Ann Rheum Dis       Date:  2002-11       Impact factor: 19.103

4.  Chemical and Biochemical Basis of Cell-Bone Matrix Interaction in Health and Disease.

Authors:  Xu Feng
Journal:  Curr Chem Biol       Date:  2009-05-01

5.  Cytochalasin Z11 inhibits RANKL-induced osteoclastogenesis via suppressing NFATc1 activation.

Authors:  Lu Wang; Kai Chen; Jianbo He; Jacob Kenny; Yu Yuan; Junhao Chen; Qian Liu; Renxiang Tan; Jinmin Zhao; Jiake Xu
Journal:  RSC Adv       Date:  2019-11-25       Impact factor: 4.036

Review 6.  Non-Canonical (RANKL-Independent) Pathways of Osteoclast Differentiation and Their Role in Musculoskeletal Diseases.

Authors:  A Sabokbar; D J Mahoney; F Hemingway; N A Athanasou
Journal:  Clin Rev Allergy Immunol       Date:  2016-08       Impact factor: 8.667

7.  Gingipains promote RANKL-induced osteoclastogenesis through the enhancement of integrin β3 in RAW264.7 cells.

Authors:  Weiyan Mo; Haoyuan Luo; Juan Wu; Na Xu; Fuping Zhang; Qihong Qiu; Wenjun Zhu; Min Liang
Journal:  J Mol Histol       Date:  2020-03-19       Impact factor: 2.611

Review 8.  Molecular regulation of osteoclast activity.

Authors:  Angela Bruzzaniti; Roland Baron
Journal:  Rev Endocr Metab Disord       Date:  2006-06       Impact factor: 9.306

9.  MyD88 primes macrophages for full-scale activation by interferon-gamma yet mediates few responses to Mycobacterium tuberculosis.

Authors:  Shuangping Shi; Carl Nathan; Dirk Schnappinger; Jörg Drenkow; Michele Fuortes; Ellen Block; Aihao Ding; Thomas R Gingeras; Gary Schoolnik; Shizuo Akira; Kiyoshi Takeda; Sabine Ehrt
Journal:  J Exp Med       Date:  2003-09-29       Impact factor: 14.307

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.